Speaker Profile
M.D., President & CEO, Lyell
Biography
Lynn Seely, M.D., has served as Lyells President and Chief Executive Officer since December 2022 and has been a member of our board of directors since May 2021. Dr. Seely was also previously the lead independent director for Blueprint Medicines Corporation acquired by Sanofi and a director for TORL BioTherapeutics.Dr. Seely was formerly President and Chief Executive Officer and a member of the board of directors of Myovant Sciences, Inc., a biopharmaceutical company that gained marketing approval and launched ORGOVYX for men with advanced prostate cancer and MYFEMBREE for women with uterine fibroids and endometriosis.Prior to joining Myovant, Dr. Seely served as the Chief Medical Officer of Medivation, Inc. In this role, Dr. Seely oversaw the development and marketing approval of the blockbuster medicine XTANDI for men with castration-resistant prostate cancer and held leadership roles in drug development collaborations with Pfizer Inc. and Astellas Pharma US, Inc.Prior to joining Medivation, Dr. Seely served as Vice President of Clinical Development at Corgentech Inc., at Cytyc Health Corporation, and at ProDuct Health, Inc., a medical device company acquired by Cytyc Corporation.Dr. Seely began her industry career in clinical development at Chiron Corporation. In addition to serving on the Lyell Board, Dr. Seely serves on the Board of Managers for Life Science Cares Bay Area.Dr. Seely received a B.A. in journalism from the University of Oklahoma and an M.D. from the University of Oklahoma College of Medicine. She completed her residency and served as Chief Resident in internal medicine at YaleNew Haven Hospital, and she completed her fellowship in endocrinology and metabolism at the University of California, San Diego, where she was on faculty before joining industry.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Priti Hegde, Kite Pharma
PMWC Award Ceremony
• Michel Sadelain, Columbia University
• Arie S. Belldegrun, Allogene Therapeutics
Keynote: Engineering the Future: Innovations in CAR-T Therapy Design
• Michel Sadelain, Columbia University
CAR-T Cell Therapies: Strategies in Mitigating Challenges in Solid Tumor Delivery
• Chair: David Barrett, Kite Pharma
• Carl June, University of Pennsylvania
• Michel Sadelain, Columbia University
Tumor-Infiltrating Lymphocytes (TILs): Advances and Challenges in Solid Tumors
• Chair: Allison Betof Warner, Stanford University
• George Coukos, Ludwig Institute for Cancer Research
• Max Julve, Royal Marsden
• Stephanie Goff, NIH/NCI
Allogeneic & In Vivo Cell Therapies: Manufacturing & Clinical Progress
• Chair: Arie S. Belldegrun, Allogene Therapeutics
• David Chang, Allogene Therapeutics
• Adrian Bot, Capstan Therapeutics
• Aliya Omer, AstraZeneca
• Priti Hegde, Kite Pharma
Designing Automated Platforms for Scalable Cell Therapy Manufacturing
• Fabian Gerlinghaus, Cellares
TCR-Based Cell Therapies: New Targets and Clinical Advances
• Chair: Diwakar Davar, UPMC
• Lauren Harshman, Clasp Therapeutics
• Cassian Yee, MD Anderson Cancer Center
Gene Editing & Synthetic Biology for Therapy
• Chair: Matthew Porteus, Stanford University
• Rachel Haurwitz, Caribou Biosciences
• Kole T. Roybal, Parker Institute
• Ken Drazan, ArsenalBio
In-Vivo Myeloid Programming: Engineering the Innate Immune System for Solid Tumor Therapy
• Daniel Getts, Create Medicines
Synthetic Circuits for Smarter Cell Therapies: Enhancing NK Precision and Persistence
• Gudrun Stengel, Alida Biosciences
